ArticleNature cell biology2013
GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression.
Article in Nature cell biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 232 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
232 citing papers in PubMed, 378 citations in OpenAlex.
- Canonical and non-canonical miRNA degradation shapes state transitions and stemness in breast cancer.The EMBO journal · 2026Article
- Dermal bone remodelling by invasive osteoblasts evolved in stem gnathostomes.bioRxiv : the preprint server for biology · 2026Article
- Targeting the microbiota-miRNA-protease axis: A new therapeutic avenue in melanoma.The FEBS journal · 2026Review
- Review
- The GATA3-RFPL3-ASK1 axis suppresses breast cancer growth and lung metastasis.Apoptosis : an international journal on programmed cell death · 2026Article
- Mesenchymal to epithelial transition (MET) in cancer progression: insights from logical modeling.Scientific reports · 2026Article
- Tumor genomics in patients younger than 40 years of age with metastatic breast cancer.NPJ precision oncology · 2026Article
- Reduced GATA3 expression associates with immuno-metabolic alterations and aggressive features in breast cancer.The journal of pathology. Clinical research · 2025Article
- GATA3 promotes ferroptosis resistance by repressing integrin β1 signaling.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Characterization of a periodontal-inflammatory microRNA profile during multibracket orthodontic treatment in adolescents.Scientific reports · 2025Article
- The potential of miR-29 in modulating tumor angiogenesis: a comprehensive review.Discover oncology · 2025Review
- Inflammation in cancer: therapeutic opportunities from new insights.Molecular cancer · 2025Review
- N6-methyladenosine RNA modification regulates the transcription of SLC7A11 through KDM6B and GATA3 to modulate ferroptosis.Journal of biomedical science · 2025Article
- Extracellular matrix dysregulation in aging, calcification, and cancer diseases: insights into cellular senescence, inflammation, and novel therapeutic strategies.International journal of biological sciences · 2025Review
- Physics-informed AI with chemical master equation dynamics for driver-gene subclone detection and risk labeling.Computational and structural biotechnology journal · 2025Article
- miRNA-Targeted Vaccines: A Promising Approach for Viral Attenuation and Immunogenicity Enhancement.Current gene therapy · 2025Review
- Screening and validating the optimal panel of housekeeping genes for 4T1 breast carcinoma and metastasis studies in mice.Scientific reports · 2024Article
- GATA3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in breast cancer.BMC biology · 2024Article
- Article
- Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies.Stem cells international · 2024Review
172 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
Despite advances in our understanding of breast cancer, patients with metastatic disease have poor prognoses. GATA3 is a transcription factor that specifies and maintains mammary luminal epithelial cell fate, and its expression is lost in breast cancer, correlating with a worse prognosis in human patients. Here, we show that GATA3 promotes differentiation, suppresses metastasis and alters the tumour microenvironment in breast cancer by inducing microRNA-29b (miR-29b) expression. Accordingly, miR-29b is enriched in luminal breast cancers and loss of miR-29b, even in GATA3-expressing cells, increases metastasis and promotes a mesenchymal phenotype. Mechanistically, miR-29b inhibits metastasis by targeting a network of pro-metastatic regulators involved in angiogenesis, collagen remodelling and proteolysis, including VEGFA, ANGPTL4, PDGF, LOX and MMP9, and targeting ITGA6, ITGB1 and TGFB, thereby indirectly affecting differentiation and epithelial plasticity. The discovery that a GATA3-miR-29b axis regulates the tumour microenvironment and inhibits metastasis opens up possibilities for therapeutic intervention in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.